These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29106602)

  • 1. PRMT5 as a druggable target for glioblastoma therapy.
    Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
    Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.
    Banasavadi-Siddegowda YK; Russell L; Frair E; Karkhanis VA; Relation T; Yoo JY; Zhang J; Sif S; Imitola J; Baiocchi R; Kaur B
    Oncogene; 2017 Jan; 36(2):263-274. PubMed ID: 27292259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma.
    Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J
    J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5 inhibition disrupts splicing and stemness in glioblastoma.
    Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB
    Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK
    Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling.
    Wu ATH; Huang HS; Wen YT; Lawal B; Mokgautsi N; Huynh TT; Hsiao M; Wei L
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
    Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.
    Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA
    Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma.
    Ashizawa T; Miyata H; Iizuka A; Komiyama M; Oshita C; Kume A; Nogami M; Yagoto M; Ito I; Oishi T; Watanabe R; Mitsuya K; Matsuno K; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Nakasu Y; Yamaguchi K; Akiyama Y
    Int J Oncol; 2013 Jul; 43(1):219-27. PubMed ID: 23612755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
    Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
    Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
    McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
    Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phostine PST3.1a Targets MGAT5 and Inhibits Glioblastoma-Initiating Cell Invasiveness and Proliferation.
    Hassani Z; Saleh A; Turpault S; Khiati S; Morelle W; Vignon J; Hugnot JP; Uro-Coste E; Legrand P; Delaforge M; Loiseau S; Clarion L; Lecouvey M; Volle JN; Virieux D; Pirat JL; Duffau H; Bakalara N
    Mol Cancer Res; 2017 Oct; 15(10):1376-1387. PubMed ID: 28634226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Type Ca
    Visa A; Sallán MC; Maiques O; Alza L; Talavera E; López-Ortega R; Santacana M; Herreros J; Cantí C
    Cancer Res; 2019 Apr; 79(8):1857-1868. PubMed ID: 30755443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
    Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
    Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma.
    Narayan RS; Gasol A; Slangen PLG; Cornelissen FMG; Lagerweij T; Veldman HYYE; Dik R; van den Berg J; Slotman BJ; Würdinger T; Haas-Kogan DA; Stalpers LJA; Baumert BG; Westerman BA; Theys J; Sminia P
    Mol Cancer Ther; 2018 Feb; 17(2):347-354. PubMed ID: 28958992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.